PCV8 Patient Reported Outcomes Asssesment of Thai Chronic Stable Angina Pectoris(CSAP)  by Rojkajornnaphalai, S.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A513
patients, riociguat increased the proportion fulfilling criteria defining a positive 
response to therapy.
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Objectives: A pilot test to assess patient-centered outcomes in daily manage-
ment of coronary artery disease at cardiology clinics in Thailand. MethOds: A 
Delphi method was used for development of PRO questionnaire assessing along 
with ivabradine treatment from randomly selected CSAP patients under the Health 
Authorities’ pharmacovigilance monitoring program. A 15-items short-form health 
survey with 5 response choices adopted with permission from validity-tested PRO 
used in medical outcomes study in Thai patients, four health dimensions included 
general, physical, social function role limiting and mental health dimensions with 
1, 6, 5 and 3 items each respectively. Standardized scoring was calculated with 
the lowest(0) to highest(100). Field tests among healthy volunteers performed.The 
reliability test employed inter-item and intra-item consistency using Cronbach’s 
alpha coefficient. All 15 items of survey were evaluated at initiation and after 
four months clinical intervention. The treatment acceptability was further 
assessed from patient interviews. Results: Of 162 patients randomly selected 
for PRO evaluation, 85(53%) was men, all patients mean(SD) age of 67.3(11.7) years 
whom 97(59.5%)was > 65 years, 9(5.5%) was smokers and 81(49.7%) had a Body 
Mass Index ≥ 25 kg/m2. Forty-three (26.4%) of patients had previous intervention 
and 63(39%) had heart failure(HF). The internal consistency of the score for all 
15 items, for physical, social function role limiting and mental health dimen-
sions, reflected Chronbach’s alpha coefficient of 0.888, 0.771, 0.702 and 0.807 at 
baseline. After 4-month, Cronbach’s alpha coefficient were of 0.735, 0.715, 0.661 
and 0.519. All mean scores(SD) of these four health dimensions, were signifi-
cantly improved from 47.59(11.50) to 54.91(9.45), from 50.33(12.11) to 54.91(10.42), 
from 39.53(10.35) to 52.68(10.32) and from 45.88(17.08) to 54.88(18.49) respectively 
(P< 0.001). cOnclusiOns: This pilot development confirms reliability of 15-items 
short-form health survey, score is consistent overtime. Thai CSAP patients who 
were prescribed ivabradine reported a highly significant improvement in qual-
ity of life including all health dimensions general, physical, social function role 
limiting and mental health. Patient-reported outcomes questionnaires could be 
recommended alongside clinical treatment.
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Objectives: European guidelines support LDL-C goals based on an individual’s 
absolute cardiovascular (CV) risk and have established a goal of < 70 mg/dL in very 
high CV risk patients. The objective of this study was to estimate the proportion of 
individuals that attain these goals and assess the determinants of any observed 
variation. MethOds: Patients in The Health Improvement Network (THIN) UK 
general practice database with an LDL-C measurement during 2011 and at very 
high risk of CV risk events were identified and further categorized as recent acute 
coronary syndrome (ACS, within 6 months pre LDL-C measurement), prior coronary 
events, stroke, and peripheral vascular disease (PVD). Lipid-lowering therapy (LLT) 
was categorized as high-potency statin, standard-potency statin, non-statin LLT, 
and no LLT. Results: In total, 25,535 patients met the inclusion criterion. Median 
(inter-quartile range [IQR]) age was 71 (62 to 79) years, 63.5% were male, and median 
(IQR) LDL-C was 108 (83 to 139) mg/dL. Across the total cohort, 6.3%, 61.3%, 17.8%, and 
14.6% had evidence of recent ACS, prior coronary events, stroke, and PVD. Patients 
with LDL-C < 70 mg/dL within these categories were 18.9%, 13.5%, 14.5%, and 11.4%. 
Across the total cohort, 16.0%, 52.5%, 0.5%, and 31.0% were on high-potency statin, 
standard-potency statin, non-statin LLT, and no LLT. Patients with LDL-C < 70 mg/
dL within these LLT categories were 18.3%, 15.4%, 11.6%, and 8.5%. cOnclusiOns: 
In a large, contemporary cohort of very high CV risk patients, few achieved the 
optimal LDL-C goal of < 70 mg/dL. One third were not on any LLT, < 20% were on 
high-potency statin, and > 80% of those receiving high-potency statins were not at 
LDL-C goal. These data suggest the need for ongoing efforts to improve prescribing 
of appropriate LLT as well as identifying new therapies to improve goal attainment 
among very high CV risk patients.
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Objectives: Venous thromboembolism (VTE) is a relatively common post-operative 
complication in cancer patients associated with high mortality rates. Gynae-oncology 
patients are predisposed to developing VTE due to the presence of a number of high 
risk factors. Current thromboprophylactic protocols for LMWH dosage and duration 
may be insufficient as a significant percentage of VTEs in gynae-oncology patients 
occur despite LMWH prophylaxis. The aim of this study is to investigate the antico-
agulant (anti-Xa) activity of Tinzaparin prophylaxis in the immediate post-operative 
period in gynae-oncology patients. MethOds: All patients attending St. James’s 
recommended therapeutic strategies and clinical outcomes as a function of the 
therapeutic strategies in a real world setting. MethOds: An observational retro-
spective cohort analysis based on 4 Local Health Units administrative databases 
was conducted. High CV risk patients who filled at least one prescription for high 
dosages statins between January 1, 2007-December 31, 2007 (enrolment period) 
were included. Patients were followed-up for 24 months. Patients were defined as 
adherent if they had > 80% of follow up period covered by drugs dispensation. To 
correct for potential confounders, a multivariable proportional hazards Cox regres-
sion model considering age, gender, type of statin, adherence to treatment and 
stay on treatment was assessed. Stay on treatment was defined as no switch or 
down titration during the follow up period. Results: Among 36,327 (3% of the 
population) high CV risk patients, Rosuvastatin 40mg (R40) and Atorvastatin 80mg 
(A80) were not used (0.1% each treatment); 625 (2%) patients used R20 and 908 (2%) 
A40. Stay on treatment was similar across treatments: 61% for R20 and 60% for A40 
(p= 0.583). 2.6 (1.7-3.5) CV events per 100 patients/year for R20 and 4.4 (3.4-5.4) for 
A40 were observed (p= 0.014). At the multivariable Cox regression analysis, risk of 
CV event was lower for R20, as compared to A40 (HR= 0.60, 95%CI 0.39-0.91, p= 0.017). 
Other statistically significant covariates were adherence (HR= 0.50, 95%CI 0.29-0.87, 
p= 0.015) and stay on treatment (HR= 0.58, 95%CI 0.40-0.85, p= 0.006). cOnclusiOns: 
Despite guidelines recommendations, high dosages statins are poorly used in real 
practice. Stay on treatment was similar among those treated with R20 and A40, even 
though R20 showed a lower incidence of cardiovascular events.
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Objectives: This analysis estimates the impact of switching from rosuvastatin 
to atorvastatin on cardiovascular (CV) events. MethOds: Using the Archimedes 
model, a discrete-event simulation, we evaluated a simulated population of 50,038 
patients aged 45–70 years with dyslipidemia and adherent to rosuvastatin. The 
virtual population was created based on matched biomarker profiles of patients 
in the National Health and Nutrition Examination Survey (NHANES). Statin treat-
ment models were based on data from published studies, including STELLAR, 
JUPITER, CARDS, ASCOT, and TNT. Patients were started on a rosuvastatin dose 
based on their LDL-C and ATP-III goal. Treatment prevalence was calibrated to 
match distributions of statin use observed in U.S. pharmacy claims data. In the 
experimental arm, patients switched to twice the mg atorvastatin dose as their 
rosuvastatin dose at their first follow-up visit (no switching occurred in the con-
trol arm). Patients were monitored for 5 years, during which time they received 
regular visits, with the opportunity to increase their dosage if they were above 
their LDL-C goal. Rate of first occurrence of MI, stroke, or CV death (MACE) for 
each arm was estimated. Results: After 5 years, when all patients switched to 
atorvastatin, 4.8% fewer patients reached goal, and mean LDL-C increased by 7.1 
mg/dL. The 5-year relative risk of MACE was 1.117 (95% CI 1.098–1.135), and the 
number needed to harm (NNH) to incur one additional MACE was 262, favoring 
rosuvastatin. For diabetics, the relative risk of MACE was 1.128 (95% CI 1.096–1.159), 
and the NNH to incur one additional MACE was 195, indicating greater risk for dia-
betics. The results were insensitive to assumptions of adherence rates and LDL-C 
goal values. cOnclusiOns: In this simulation, switching from rosuvastatin to 
atorvastatin led to fewer patients attaining LDL-C goal, higher mean LDL-C values, 
and greater risk of MACE over 5 years.
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Objectives: Indications for PAH medications vary between countries, and prod-
ucts may have restricted reimbursement based on policies limiting treatment to 
WHO functional class (FC) III patients. In the PATENT-1 study, the novel soluble 
guanylate cyclase stimulator riociguat significantly improved 6-minute walking 
distance (6MWD) and a range of secondary endpoints in patients with PAH. This 
subgroup analysis of PATENT-1 investigated the proportion of FC III/IV patients 
achieving threshold criteria. MethOds: PATENT-1 was a double-blind, randomized 
Phase III study in which patients with PAH received 12 weeks’ oral treatment with 
placebo, an individual titration of riociguat (up to 2.5 mg tid), or a capped titration 
of riociguat (up to 1.5 mg tid). Increase in 6MWD ≥ 40 m, 6MWD ≥ 380 m, cardiac 
index (CI) ≥ 2.5 L/min/m2, pulmonary vascular resistance (PVR) < 500 dyn·s·cm−5, 
mixed venous oxygen saturation (SvO2) ≥ 65%, FC I/II, absence of clinical worsen-
ing events, and NT-proBNP < 1800 pg/mL were chosen as positive response criteria 
based on studies showing their prognostic relevance at baseline and after targeted 
therapy. Results: At baseline, 241 patients were in FC III/IV (FC IV n= 4) across 
the three treatment groups, and similar proportions met selected criteria in the 
riociguat individual titration (n= 141) and placebo groups (n= 61). At Week 12/last 
visit, the proportion of patients fulfilling these criteria was higher in the riociguat 
individual titration group than the placebo group for all parameters: increase in 
6MWD ≥ 40m (44% vs 15%), 6MWD ≥ 380m (49% vs 36%), CI ≥ 2.5 L/min/m2 (75% vs 
43%), PVR < 500 dyn·s·cm−5 (52% vs 27%), SvO2 ≥ 65% (68% vs 35%), FC I/II (33% vs 
23%), absence of clinical worsening events (99% vs 90%), and NT-proBNP < 1800 pg/
mL (84% vs 64%). cOnclusiOns: In this population of predominantly FC III PAH 
